Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | NTRK1 amp |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| NTRK1 amp | esophagus squamous cell carcinoma | predicted - sensitive | Larotrectinib | Case Reports/Case Series | Actionable | In a clinical case study, Vitrakvi (larotrectinib) resulted in a partial response with regression of both the primary tumor and metastatic lesions within 6 weeks from the start of treatment in a patient with squamous cell esophageal carcinoma with NTRK1 amplification (PMID: 32323889). | 32323889 |